Takura has acquired all shares in clinical stage immuno-oncology company Polybiocept GmbH (PBC). Takura was already a minority owner in the company which owns a patent portfolio for TIL (tumor infiltrating lymphocytes) therapy. Immunotherapy is one of the fastest growing segments in the pharmaceutical industry and has the potential to revolutionize cancer care. PBC has a collaboration with Krankenhaus Nordwest (KHNW) in Frankfurt where 16 patients with solid cancers have been treated with PBC’s technology under hospital exemption. The company has now started to plan for a phase I clinical trial.
https://takura.se/wp-content/uploads/2019/10/takura-300x89.png 0 0 Maria Rankka https://takura.se/wp-content/uploads/2019/10/takura-300x89.png Maria Rankka2020-07-14 20:19:212020-07-14 20:19:21Takura acquires Polybiocept GmbH
Takura is a Swedish company that commercializes advanced cell therapy research in order to accelerate the development and make groundbreaking treatments accessible and more affordable.